Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow

Wang, 2018, IgG Fc engineering to modulate antibody effector functions, Protein Cell, 9, 63, 10.1007/s13238-017-0473-8 Sela-Culang, 2013, The structural basis of antibody-antigen recognition, Front. Immunol., 4, 302, 10.3389/fimmu.2013.00302 Lipman, 2005, Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources, ILAR J., 46, 258, 10.1093/ilar.46.3.258 Kaplon, 2018, Antibodies to watch in 2018, MAbs, 10, 183, 10.1080/19420862.2018.1415671 Rudnick, 2009, Affinity and avidity in antibody-based tumor targeting, Cancer Biother. Radiopharm., 24, 155, 10.1089/cbr.2009.0627 Cuesta, 2010, Multivalent antibodies: when design surpasses evolution, Trends Biotechnol., 28, 355, 10.1016/j.tibtech.2010.03.007 Chames, 2009, Bispecific antibodies for cancer therapy: the light at the end of the tunnel?, MAbs, 1, 539, 10.4161/mabs.1.6.10015 Arezumand, 2017, Nanobodies as novel agents for targeting angiogenesis in solid cancers, Front. Immunol., 8, 1746, 10.3389/fimmu.2017.01746 Fan, 2015, Bispecific antibodies and their applications, J. Hematol. Oncol., 8, 130, 10.1186/s13045-015-0227-0 Jamnani, 2012, Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells, Exp. Cell Res., 318, 1112, 10.1016/j.yexcr.2012.03.004 Spiess, 2015, Alternative molecular formats and therapeutic applications for bispecific antibodies, Mol. Immunol., 67, 95, 10.1016/j.molimm.2015.01.003 Kontermann, 2015, Bispecific antibodies, Drug Discov. Today, 20, 838, 10.1016/j.drudis.2015.02.008 Kontermann, 2012, Dual targeting strategies with bispecific antibodies, MAbs, 4, 182, 10.4161/mabs.4.2.19000 Nyakatura, 2017, Bispecific antibodies for viral immunotherapy, Hum. Vaccin. Immunother., 13, 836, 10.1080/21645515.2016.1251536 Wu, 2015, AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy, J. Hematol. Oncol., 8, 96, 10.1186/s13045-015-0188-3 Brischwein, 2006, MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors, Mol. Immunol., 43, 1129, 10.1016/j.molimm.2005.07.034 McDonagh, 2012, Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3, Mol. Cancer Ther., 11, 582, 10.1158/1535-7163.MCT-11-0820 DiGiandomenico, 2014, A multifunctional bispecific antibody protects against Pseudomonas aeruginosa, Sci. Transl. Med., 6, 262ra155, 10.1126/scitranslmed.3009655 Mouquet, 2012, Enhanced HIV-1 neutralization by antibody heteroligation, Proc. Natl. Acad. Sci. USA, 109, 875, 10.1073/pnas.1120059109 Zhang, 2017, The development of bispecific antibodies and their applications in tumor immune escape, Exp. Hematol. Oncol., 6, 12, 10.1186/s40164-017-0072-7 Brinkmann, 2017, The making of bispecific antibodies, MAbs, 9, 182, 10.1080/19420862.2016.1268307 Lehmann, 2016, In vivo fluorescence imaging of the activity of CEA TCB, a novel T-cell bispecific antibody, reveals highly specific tumor targeting and fast induction of T-cell-mediated tumor killing, Clin. Cancer Res., 22, 4417, 10.1158/1078-0432.CCR-15-2622 Weidle, 2014, Tumor-antigen-binding bispecific antibodies for cancer treatment, Semin. Oncol., 41, 653, 10.1053/j.seminoncol.2014.08.004 Monnier, 2013, In vivo applications of single chain Fv (variable domain) (scFv) fragments, Antibodies, 2, 193, 10.3390/antib2020193 Wang, 2014, Combination of specific single chain antibody variable fragment and siRNA has a synergistic inhibitory effect on the propagation of avian influenza virus H5N1 in chicken cells, Virol. J., 11, 208, 10.1186/s12985-014-0208-x Pishko, 2017, The role of novel immunotherapies in non-Hodgkin lymphoma, Transl. Cancer Res., 6, 93, 10.21037/tcr.2017.01.08 Hipp, 2017, A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo, Leukemia, 31, 1743, 10.1038/leu.2016.388 Zhu, 2016, Blinatumomab, a bispecific T-cell engager (BiTE(®)) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications, Clin. Pharmacokinet., 55, 1271, 10.1007/s40262-016-0405-4 Root, 2016, Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer, Antibodies, 5, 6, 10.3390/antib5010006 Thakur, 2016, “NextGen” biologics: bispecific antibodies and emerging clinical results, Expert Opin. Biol. Ther., 16, 675, 10.1517/14712598.2016.1150996 Walseng, 2016, Chemically programmed bispecific antibodies in diabody format, J. Biol. Chem., 291, 19661, 10.1074/jbc.M116.745588 Compte, 2007, Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes, Cancer Gene Ther., 14, 380, 10.1038/sj.cgt.7701021 Compte, 2010, Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system, Gene Ther., 17, 745, 10.1038/gt.2010.33 Blanco, 2003, Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells, J. Immunol., 171, 1070, 10.4049/jimmunol.171.2.1070 Compte, 2014, Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications, OncoImmunology, 3, e28810, 10.4161/onci.28810 Mølgaard, 2017, Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity, Gene Ther., 24, 208, 10.1038/gt.2017.3 Ahmed, 2015, Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody, OncoImmunology, 4, e989776, 10.4161/2162402X.2014.989776 Joint United Nations Programme on HIV/AIDS (UNAIDS). (2018). UNAIDS Data 2018. http://www.unaids.org/en/resources/documents/2018/unaids-data-2018. Pham, 2018, The latest evidence for possible HIV-1 curative strategies, Drugs Context, 7, 212522, 10.7573/dic.212522 Kimata, 2016, Challenges and strategies for the eradication of the HIV reservoir, Curr. Opin. Immunol., 42, 65, 10.1016/j.coi.2016.05.015 Bournazos, 2016, Bispecific anti-HIV-1 antibodies with enhanced breadth and potency, Cell, 165, 1609, 10.1016/j.cell.2016.04.050 Wagh, 2018, Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections, PLoS Pathog., 14, e1006860, 10.1371/journal.ppat.1006860 Wu, 2018, Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice, J. Clin. Invest., 128, 2239, 10.1172/JCI96764 Huang, 2016, Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity, Cell, 165, 1621, 10.1016/j.cell.2016.05.024 Sung, 2015, Dual-affinity re-targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells, J. Clin. Invest., 125, 4077, 10.1172/JCI82314 Wei, 2017, Structural basis of a novel heterodimeric Fc for bispecific antibody production, Oncotarget, 8, 51037, 10.18632/oncotarget.17558 Gunasekaran, 2010, Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG, J. Biol. Chem., 285, 19637, 10.1074/jbc.M110.117382 Dheilly, 2017, Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies, Mol. Ther., 25, 523, 10.1016/j.ymthe.2016.11.006 Piccione, 2015, A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells, MAbs, 7, 946, 10.1080/19420862.2015.1062192 van Bommel, 2017, CD20-selective inhibition of CD47-SIRPα “don’t eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab, OncoImmunology, 7, e1386361, 10.1080/2162402X.2017.1386361 Gan, 2013, The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered, FEBS J., 280, 5350, 10.1111/febs.12393 An, 2018, Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies, Oncogene, 37, 1561, 10.1038/s41388-017-0045-7 Ellwanger, 2017, Highly specific and effective targeting of EGFRvIII-positive tumors with TandAb antibodies, Front. Oncol., 7, 100, 10.3389/fonc.2017.00100 Gedeon, 2018, A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma, Clin. Cancer Res., 24, 3611, 10.1158/1078-0432.CCR-17-0126 Jin, 2008, Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer, J. Mammary Gland Biol. Neoplasia, 13, 485, 10.1007/s10911-008-9107-3 Weigelt, 2010, HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment, Breast Cancer Res. Treat., 122, 35, 10.1007/s10549-009-0502-2 Moasser, 2007, The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis, Oncogene, 26, 6469, 10.1038/sj.onc.1210477 Araki, 2017, First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer, Breast, 35, 78, 10.1016/j.breast.2017.06.015 Xing, 2017, BiHC, a T-cell–engaging bispecific recombinant antibody, has potent cytotoxic activity against Her2 tumor cells, Transl. Oncol., 10, 780, 10.1016/j.tranon.2017.07.003 Sharifzadeh, 2013, Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen, Mol. Biotechnol., 54, 590, 10.1007/s12033-012-9601-0 Ferrari, 2015, Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro, J. Exp. Clin. Cancer Res., 34, 123, 10.1186/s13046-015-0241-7 Kebenko, 2018, A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors, OncoImmunology, 7, e1450710, 10.1080/2162402X.2018.1450710 Trzpis, 2007, Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule, Am. J. Pathol., 171, 386, 10.2353/ajpath.2007.070152 Sedykh, 2018, Bispecific antibodies: design, therapy, perspectives, Drug Des. Devel. Ther., 12, 195, 10.2147/DDDT.S151282 Eskander, 2013, Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer, Clin. Pharmacol., 5, 55 Lutterbuese, 2009, Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA, J. Immunother., 32, 341, 10.1097/CJI.0b013e31819b7c70 Osada, 2010, Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody, Br. J. Cancer, 102, 124, 10.1038/sj.bjc.6605364 Oberst, 2014, CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas, MAbs, 6, 1571, 10.4161/19420862.2014.975660 Kischel, 2009, Abstract #3252: Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110, Cancer Res., 69, 3252 Pishvaian, 2016, Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas, Clin. Colorectal Cancer, 15, 345, 10.1016/j.clcc.2016.07.009 Moek, 2018, Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma, Ann. Oncol., 29, 10.1093/annonc/mdy279.414 Friedrich, 2012, Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens, Mol. Cancer Ther., 11, 2664, 10.1158/1535-7163.MCT-12-0042 Siegel, 2018, Cancer statistics, 2018, CA Cancer J. Clin., 68, 7, 10.3322/caac.21442 Bravaccini, 2018, PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis, Sci. Rep., 8, 4254, 10.1038/s41598-018-22594-1 von Eyben, 2018, PSMA diagnostics and treatments of prostate cancer become mature, Clin. Transl. Imaging, 6, 145, 10.1007/s40336-018-0270-2 Bühler, 2008, A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells, Cancer Immunol. Immunother., 57, 43, 10.1007/s00262-007-0348-6 Bühler, 2009, Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells, J. Immunother., 32, 565, 10.1097/CJI.0b013e3181a697eb Fortmüller, 2011, Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody, Prostate, 71, 588, 10.1002/pros.21274 Kipriyanov, 1997, Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity, Protein Eng., 10, 445, 10.1093/protein/10.4.445 The Leukemia & Lymphoma Society. (2018). Facts 2017-2018. https://www.lls.org/sites/default/files/file_assets/PS80_Facts2017-2018.pdf. Showel, 2014, Advances in treating acute myeloid leukemia, F1000Prime Rep., 6, 96, 10.12703/P6-96 Perl, 2017, The role of targeted therapy in the management of patients with AML, Hematology (Am. Soc. Hematol. Educ. Program), 2017, 54, 10.1182/asheducation-2017.1.54 Schürch, 2018, Therapeutic antibodies for myeloid neoplasms-current developments and future directions, Front. Oncol., 8, 152, 10.3389/fonc.2018.00152 Laing, 2017, Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia, Exp. Hematol., 54, 40, 10.1016/j.exphem.2017.06.007 Ehninger, 2014, Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia, Blood Cancer J., 4, e218, 10.1038/bcj.2014.39 Friedrich, 2014, Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia, Mol. Cancer Ther., 13, 1549, 10.1158/1535-7163.MCT-13-0956 Laszlo, 2014, Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML, Blood, 123, 554, 10.1182/blood-2013-09-527044 Aigner, 2013, T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct, Leukemia, 27, 1107, 10.1038/leu.2012.341 Ravandi, 2018, A phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE®) antibody construct, in relapsed/refractory acute myeloid leukemia (R/R AML), Blood, 132, 25, 10.1182/blood-2018-99-109762 Carpenter, 2013, B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma, Clin. Cancer Res., 19, 2048, 10.1158/1078-0432.CCR-12-2422 Li, 2017, Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis, PLoS ONE, 12, e0181447, 10.1371/journal.pone.0181447 Cho, 2018, Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy, Front. Immunol., 9, 1821, 10.3389/fimmu.2018.01821 Topp, 2018, Blood, 132, 1010, 10.1182/blood-2018-99-109769 Wang, 2012, CD19: a biomarker for B cell development, lymphoma diagnosis and therapy, Exp. Hematol. Oncol., 1, 36, 10.1186/2162-3619-1-36 Reusch, 2015, A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells, MAbs, 7, 584, 10.1080/19420862.2015.1029216 GlobeNewswire (2018). Affimed places AFM11 (CD19/CD3-targeting T cell engager) phase 1 program on clinical hold. https://www.globenewswire.com/news-release/2018/10/08/1618171/0/en/Affimed-Places-AFM11-CD19-CD3-Targeting-T-cell-Engager-Phase-1-Program-on-Clinical-Hold.html. Liu, 2017, MGD011, a CD19 x CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies, Clin. Cancer Res., 23, 1506, 10.1158/1078-0432.CCR-16-0666 Liu, 2014, MGD011, humanized CD19 × CD3 DART® protein with enhanced pharmacokinetic properties, demonstrates potent T-Cell mediated anti-tumor activity in preclinical models and durable B-cell depletion in cynomolgus monkeys following once-a-week dosing, Blood, 124, 1775, 10.1182/blood.V124.21.1775.1775 House, D.W. (2017). Janssen bails on duvortuxizumab development deal with MacroGenics after neurotoxicity observed in early-stage study. https://seekingalpha.com/news/3293160-janssen-bails-duvortuxizumab-development-deal-macrogenics-neurotoxicity-observed-early-stage. MacroGenics (2017). MacroGenics announces termination of duvortuxizumab collaboration and license agreement with Janssen. http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-announces-termination-duvortuxizumab-collaboration. Fisher, 2018, A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice, Cancer Immunol. Immunother., 67, 247, 10.1007/s00262-017-2081-0 Testa, 2014, CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies, Biomark. Res., 2, 4, 10.1186/2050-7771-2-4 Al-Hussaini, 2016, Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform, Blood, 127, 122, 10.1182/blood-2014-05-575704 Wittwer, 2017, High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression, Blood Adv., 1, 1067, 10.1182/bloodadvances.2016002931 Chichili, 2015, A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates, Sci. Transl. Med., 7, 289ra82, 10.1126/scitranslmed.aaa5693 Vey, 2017, Interim results from a phase 1 first-in-human study of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in AML/MDS, Ann. Oncol., 28, 10.1093/annonc/mdx373.001 He, 2018, Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells, EMBO J., 37, e97980, 10.15252/embj.201797980 Veri, 2010, Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold, Arthritis Rheum., 62, 1933 Stohl, 2013, Future prospects in biologic therapy for systemic lupus erythematosus, Nat. Rev. Rheumatol., 9, 705, 10.1038/nrrheum.2013.136 Pandya, 2016, Safety, tolerability, and functional activity of MGD010, a Dart® molecule targeting CD32B and CD79B, following a single dose administration in healthy volunteers, Ann. Rheum. Dis., 75, 132, 10.1136/annrheumdis-2016-eular.4079 Chen, 2017, SAT0027 Immunomodulatory effects of MGD010, a dart® molecule targeting human B-cell CD32B and CD79B, Ann. Rheum. Dis., 76, 777 Blazar, 2004, CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease, J. Immunol., 173, 2933, 10.4049/jimmunol.173.5.2933 Hu, 2013, CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study, Blood, 121, 2715, 10.1182/blood-2012-10-461848 van der Weyden, 2017, Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions, Blood Cancer J., 7, e603, 10.1038/bcj.2017.85 Jacobsen, 2015, Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression, Blood, 125, 1394, 10.1182/blood-2014-09-598763 Bhatt, 2013, CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma, Blood, 122, 1233, 10.1182/blood-2013-01-481713 Rothe, 2015, A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma, Blood, 125, 4024, 10.1182/blood-2014-12-614636 Reusch, 2014, A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells, MAbs, 6, 728, 10.4161/mabs.28591 CNBC. (2018). Affimed reports financial results for fourth quarter and year end 2017. https://www.cnbc.com/2018/03/20/globe-newswire-affimed-reports-financial-results-for-fourth-quarter-and-year-end-2017.html. Zhao, 2015, CD30/CD16A Tandab AFM13-induced target cell lysis by NK-cells is enhanced by CD137 co-stimulation and blocking PD-1, Blood, 126, 2747, 10.1182/blood.V126.23.2747.2747 Armand, 2016, Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure, J. Clin. Oncol., 34, 3733, 10.1200/JCO.2016.67.3467 Chen, 2017, Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma, J. Clin. Oncol., 35, 2125, 10.1200/JCO.2016.72.1316 Bartlett, 2018, A phase 1b study investigating the combination of the tetravalent bispecific NK cell engager AFM13 and pembrolizumab in patients with relapsed/refractory Hodgkin lymphoma after brentuximab vedotin failure: updated safety and efficacy data, Blood, 132, 1620, 10.1182/blood-2018-99-118506 GlobeNewswire. (2018). Affimed reports new data for AFM13 from two separate clinical trials in Hodgkin and CD30-positive lymphomas. https://www.globenewswire.com/news-release/2018/02/01/1330095/0/en/Affimed-Reports-New-Data-for-AFM13-from-Two-Separate-Clinical-Trials-in-Hodgkin-and-CD30-Positive-Lymphomas.html. Richards, 2014, A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors, J. Clin. Oncol., 32, 651, 10.1200/jco.2014.32.15_suppl.651 Kirouac, 2013, Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors, Sci. Signal., 6, ra68, 10.1126/scisignal.2004008 Yu, 2017, Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment, Exp. Hematol. Oncol., 6, 31, 10.1186/s40164-017-0091-4 Zhang, 2013, Abstract 4633: MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer, Cancer Res., 73, 4633, 10.1158/1538-7445.AM2013-4633 Zhang, 2012, Abstract 1888: MM-111, a bispecific HER2 and HER3 antibody, inhibits trastuzumab-resistant tumor cell growth, Cancer Res., 72, 1888, 10.1158/1538-7445.AM2012-1888 Merrimack (2014). Merrimack Pharmaceuticals presents phase 1 clinical data supporting four novel antibody therapeutic programs at the 2014 ASCO Annual Meeting. http://investors.merrimackpharma.com/news-releases/news-release-details/merrimack-pharmaceuticals-presents-phase-1-clinical-data. Isakoff, 2016, A phase 1 study of MM-141, a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3, in relapsed or refractory solid tumors, Eur. J. Cancer, 69, S137, 10.1016/S0959-8049(16)33008-8 Fitzgerald, 2014, MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors, Mol. Cancer Ther., 13, 410, 10.1158/1535-7163.MCT-13-0255 Isakoff, 2015, First-in-human study of MM-141: a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3, J. Clin. Oncol., 33, 384, 10.1200/jco.2015.33.3_suppl.384 Ko, 2018, CARRIE: a randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer, Ann. Oncol., 29, 10.1093/annonc/mdy424.031 Irani, 2018, The inhibitory effect of the combination of two new peptides on biofilm formation by Acinetobacter baumannii, Microb. Pathog., 121, 310, 10.1016/j.micpath.2018.05.051 Thanabalasuriar, 2017, Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature, J. Clin. Invest., 127, 2249, 10.1172/JCI89652 Bezabeh, 2017, Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties, MAbs, 9, 240, 10.1080/19420862.2016.1270492 Tabor, 2018, Pseudomonas aeruginosa PcrV and Psl, the molecular targets of bispecific antibody MEDI3902, are conserved among diverse global clinical isolates, J. Infect. Dis., 218, 1983 Ali, 2018, Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults, Clin. Microbiol. Infect. Kantarjian, 2017, Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia, N. Engl. J. Med., 376, 836, 10.1056/NEJMoa1609783 Larson, R.A. (2018). Treatment of relapsed or refractory acute lymphoblastic leukemia in adults. https://www.uptodate.com/home/linking-policy?&redirect=true. Wei, 2017, Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia, J. Hematol. Oncol., 10, 150, 10.1186/s13045-017-0516-x Ajorloo, 2017, A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma, PLoS ONE, 12, e0183969, 10.1371/journal.pone.0183969 Pazhouhandeh, 2017, Comparative network analysis of patients with non-small cell lung cancer and smokers for representing potential therapeutic targets, Sci. Rep., 7, 13812, 10.1038/s41598-017-14195-1 Pazhouhandeh, 2018, A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients, Clin. Exp. Immunol., 192, 18, 10.1111/cei.13087 Lyman, 2018, A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases, J. Biol. Chem., 293, 9326, 10.1074/jbc.M117.818559 Mullard, 2017, Bispecific antibody pipeline moves beyond oncology, Nat. Rev. Drug Discov., 16, 666